CytomX Therapeutics, Inc. Stock News

CytomX (CTMX) is advancing its ADC candidate CX-2051 in the oncological field. CX-2051 shows an impressive response rate and improved progression-free survival in heavily pretreated colorectal cancer patients, outperforming current therapies. Investment in CTMX is high risk and binary, but promising science and early clinical data support a speculative Buy for risk-tolerant investors.

CytomX Therapeutics, Inc. ( CTMX ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Chris Ogden - SVP & Chief Financial Officer Sean McCarthy - Chairman & CEO Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Nabeel Nissar - Jefferies LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Matthew Biegler - Opp...

- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) in melanoma - - Company to host conference call today at 5 p.m. EST / 2 p.m.

Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launchin...

- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m....

Leadership team addition to drive strategic long-term value creation and partnering strategy Leadership team addition to drive strategic long-term value creation and partnering strategy

CytomX Therapeutics presents a trade opportunity centered on upcoming Q1'26 clinical data for its masked, EpCAM-targeting, antibody-drug conjugate. Previous phase 1 data showed a compelling response rate given the late stage of the colorectal cancer patients enrolled in the study. CTMX finished Q2'25 with $158.1M in cash, which it expects to last into Q2'27.